反应详情

To a stirred suspension of the HCl salt of methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate (31.6 mg, 0.08 mmol) and (S)-4-nitrophenyl 2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamate (45 mg, 0.105 mmol) in MeCN (1 mL) and CH2Cl2 (1 mL) was added DIEA (80 μL, 0.45 mmol). The mixture was stirred at rt for 3 d, diluted with ether (90 mL), washed with 5% aq HCl (20 mL), IM aq NaOH (20 mL) and brine (20 mL), and dried over MgSO4. Removal of the solvent left a white solid (61 mg) which was applied to a 2-g silica SPE cartridge. The cartridge was eluted sequentially with 0, 25, 50, 75 and 100% EtOAc in hexanes (15 mL of each) to afford five fractions. Fractions 4 and 5 were pooled and concentrated to afford methyl (S)-4-((R)-1-((S)-2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate (35 mg) as an oil.

1. washwashed with 5% aq HCl (20 mL), IM aq NaOH (20 mL) and brine (20 mL)
2. dry with materialdried over MgSO4
3. customRemoval of the solvent
4. waitleft a white solid (61 mg) which
5. washThe cartridge was eluted sequentially with 0, 25, 50, 75 and 100% EtOAc in hexanes (15 mL of each)
6. customto afford five fractions
7. concentrationconcentrated